EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer

Koji Teramoto iD, Ryosuke Kaku, Tomoyuki Igarashi, Masayuki Hashimoto iD, Shoji Kitamura, Makoto Motoishi, Yuji Suzumura, Satoru Sawai, Yataro Daigo, Jun Hanaoka

Cancer Science · 2026

DOI: 10.1111/cas.70446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Koji Teramoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shiga University of Medical Science, Otsu, Shiga, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Docetaxel, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shiga Prefecture (Japan).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nedaplatin is a second‐generation platinum compound with reduced nephrotoxicity compared with cisplatin. Given its favorable tolerability in advanced non‐small cell lung cancer (NSCLC), we prospectively evaluated the tolerability and efficacy of an adjuvant nedaplatin plus docetaxel chemotherapy regimen in patients with completely resected NSCLC. Patients with stage IB–IIIA NSCLC who had undergone complete surgical resection received nedaplatin (80 mg/m 2 ) and docetaxel (60 mg/m 2 ) intravenously on day 1 once every 4 weeks for up to four cycles. The primary endpoint was treatment tolerability, defined as completion of the planned four cycles, and compared with historical data for the standard cisplatin plus vinorelbine regimen. The secondary endpoint was efficacy, determined by relapse‐free survival (RFS) after surgery. Thirty‐five patients were enrolled, with median age of 65 years (range, 36–77 years). Adenocarcinoma (57.1%) and stage II disease (60.0%) were most common. Dose reductions were needed in some patients, however, 74.3% of patients ( n = 26) completed all four cycles, meeting the primary endpoint. Grade 3 or 4 neutropenia and anorexia occurred in 67.8% and 9.0% of patients, respectively. No grade 3 or 4 renal dysfunction was noted. Concerning efficacy, the median RFS time was 63 months (95% confidence interval [CI], 20–NE), and the 5‐year overall survival rate was 85.7% (95% CI, 70.0–93.9). Long‐term retrospective follow‐up (median: 119 months) showed that the 10‐year RFS rate was 52.9% (95% CI, 36.1–69.1). These results indicate that adjuvant chemotherapy with nedaplatin plus docetaxel is tolerable and effective in patients with completely resected NSCLC. Trial Registration: UMIN number: 000004634

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDocetaxelLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsOrganoplatinum CompoundsHumansFemaleMiddle AgedAgedMaleAdultProspective StudiesChemotherapy, AdjuvantTreatment OutcomeDisease-Free SurvivalNeoplasm Staging

Stichwörter der Autor:innen

adjuvant chemotherapydocetaxelnedaplatinnon‐small cell lung cancertolerability

Substanzen

DocetaxelnedaplatinOrganoplatinum Compounds

Autor:innen und Institutionen

  • Department of Medical Oncology, Shiga University of Medical Science, Otsu, Shiga, Japan.
  • Center for Advanced Medicine Against Cancer, Shiga University of Medical Science, Otsu, Shiga, Japan.
  • Department of Surgery, Shiga University of Medical Science, Shiga University of Medical Science, Otsu, Shiga, Japan.
  • Department of Thoracic Surgery, National Hospital Organization Kyoto Medical Cencer, Kyoto, Japan.
  • Department of Thoracic Surgery, Ijinkai Takeda General Hospital, Kyoto, Japan.

ORCID-Profile: Koji Teramoto, Masayuki Hashimoto

Förderung

  • Shiga Prefecture (Japan)

Zitieren

APA

Teramoto, K., Kaku, R., Igarashi, T., Hashimoto, M., Kitamura, S., Motoishi, M., Suzumura, Y., Sawai, S., Daigo, Y., & Hanaoka, J. (2026). Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer. Cancer Science. https://doi.org/10.1111/cas.70446

Vancouver

Teramoto K, Kaku R, Igarashi T, Hashimoto M, Kitamura S, Motoishi M, et al. Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer. Cancer Science. 2026. doi:10.1111/cas.70446

BibTeX
@article{Teramoto2026,
  author = {Teramoto, Koji and Kaku, Ryosuke and Igarashi, Tomoyuki and Hashimoto, Masayuki and Kitamura, Shoji and Motoishi, Makoto and Suzumura, Yuji and Sawai, Satoru and Daigo, Yataro and Hanaoka, Jun},
  title = {Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70446}
}
Kostenlos starten →